Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
Business Wire•27/10/2026•07:45 ET
0
Key Highlights
- ➤Natera featured in 25 ESMO abstracts, including 9 oral presentations
- ➤VOLGA: Persistently Signatera-negative patients achieved 91% 24-month EFS
- ➤VOLGA: Positive patients remaining positive had 55% 24-month EFS
- ➤Clarity MRD detected ctDNA in 99% of stage 2B–3B NSCLC patients
- ➤Lung ctDNA clearance before surgery or chemoradiotherapy linked to 100% 1-year EFS
Expert Statements
Thomas Powles, MD, principal investigator of VOLGA and chair of Barts Cancer Centre at St. Bartholomew’s Hospital
“Prior to radical cystectomy, patients who cleared their ctDNA as well as those who were persistently negative had excellent outcomes,”
Thomas Powles, MD, principal investigator of VOLGA and chair of Barts Cancer Centre at St. Bartholomew’s Hospital
“This supports our conviction that ultrasensitive ctDNA detection with Signatera can help guide treatment decisions in bladder cancer.”
Minetta Liu, MD, Chief Medical Officer, Oncology and Early Cancer Detection, Natera
“This year’s ESMO program showcases the potential of ctDNA actionability at key decision points, including before cystectomy in bladder cancer and during neoadjuvant therapy in lung cancer,”
Minetta Liu, MD, Chief Medical Officer, Oncology and Early Cancer Detection, Natera
“Along with data in breast, gastroesophageal, colorectal and other cancers, this evidence highlights how ctDNA testing can guide patient care and improve cancer-related outcomes.”
Signatera(™ )Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO Open
Get started
Create a free account to read the full story.